CD3-directed Antibody Interactions [MoA] - N0000175617

Pharmacologic Code	N0000175617
Pharmacologic Name	CD3-directed Antibody Interactions
Pharmacologic Uses	bispecific CD19-directed CD3 T-cell engager bispecific CD20-directed CD3 T-cell engager bispecific gp100 peptide-HLA-directed CD3 T cell engager CD3 blocker immunosuppressant (antibody) CD3-directed antibody
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

The table contains 6 products whose active ingredient are classified under the same pharmacologic class CD3-directed Antibody Interactions [MoA].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	50242-125	Columvi	Non-Proprietary Name: Glofitamab	Solution, Concentrate	Intravenous	Genentech, Inc.	ACTIVE
	50242-127	Columvi	Non-Proprietary Name: Glofitamab	Concentrate	Intravenous	Genentech, Inc.	ACTIVE
	73650-316	Tzield	Non-Proprietary Name: Teplizumab-mzwv	Injection	Intravenous	Provention Bio, Inc.	ACTIVE
	80446-401	Kimmtrak	Non-Proprietary Name: Tebentafusp	Injection, Solution, Concentrate	Intravenous	Immunocore Commercial Llc	ACTIVE
	82705-002	Epkinly	Non-Proprietary Name: Epcoritamab-bysp	Injection, Solution	Subcutaneous	Genmab Us, Inc.	ACTIVE
	82705-010	Epkinly	Non-Proprietary Name: Epcoritamab-bysp	Injection, Solution	Subcutaneous	Genmab Us, Inc.	ACTIVE